Form 4: Director Leslie C. Davis Receives EW Stock Grant

Director Leslie C. Davis was granted 3,251 restricted stock units by Edwards Lifesciences Corporation.

Summary

• Director Leslie C. Davis received a grant of 3,251 restricted stock units (RSUs) on May 8, 2026.
• The grant was issued under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program.
• Following this transaction, the director's total beneficial ownership of common stock increased to 9,834 shares.
• The RSUs are scheduled to vest fully after one year or at the next annual meeting of stockholders, whichever occurs first.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial strategy.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None.

Risks

• Standard market risks associated with equity ownership.

Future Outlook

The RSUs are set to vest in one year or upon the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the medical device industry to ensure long-term alignment with shareholder value.

Comparison to Industry Standards

• The grant follows standard industry practices for director compensation in large-cap healthcare companies.
• The vesting schedule is consistent with typical one-year cliff vesting periods for board members.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact; reflects standard director compensation.

Next Steps

• Vesting of 3,251 restricted stock units in one year or at the next annual meeting.

Key Dates

Keywords

Edwards Lifesciences, EW, Director Compensation, Insider Transaction, Restricted Stock Units